Shinpoong Pharmaceutical

At a glance

Shinpoong Pharmaceutical filed 31 disclosures in the last 12 months, including 3 buyback, 1 contract and 1 issuance. The most recent key filing was on Feb 26.

Revenue for 2025 was ₩235B, up 6.1% on 2024. Operating margin was 6.1% against -9.3% a year earlier. Debt was 30% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩118B and operating loss of ₩8.4B.

The 2025 annual report lists 792 employees with an average tenure of 12 years and average pay of ₩77.1M, #440 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩86.3M each on average. It paid no cash dividend for 2025. (주)송암사 and related parties held 24.43% at year end.

From the 2025 annual report

Staff: 792 (526 men, 266 women), of whom 11 on fixed-term contracts. Total pay for the year: ₩61.1B. Directors and auditors: 5, paid ₩431.4M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)송암사 holds 24.20%; with 2 related parties the group holds 24.43% of common shares at year end.

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary